T-cell immunotherapy (T-cell vaccination) for rheumatoid arthritis – Innovita Research

Pro-inflammatory autoreactive T lymphocytes specific for cartilage-associated antigens play a pivotal role in the development of rheumatoid arthritis. Standard treatment of rheumatoid arthritis is based on nonsteroidal anti-inflammatory drugs (NSAIDs), nonbiologic and biologic disease-modifying antirheumatic drugs (DMARDs) and non-specific (non-selective) immunosuppressants (hormones, cytostatic agents and others). This treatment fails to interrupt the underlying immunopathological events and is often associated with serious complications.

T-cell autovaccination-based technology is aimed to stimulate patient’s immune responses, which selectively inactivate pathogenic self-reactive Т lymphocytes.
Forty-two patients (age 28–58 y; 37 women, 5 men) with rheumatoid arthritis (disease history ≥2 years) were subjected to the T-cell vaccination treatment. Our clinical data (Table 1) showed that T cell vaccination of rheumatoid arthritis patients (n = 42) resulted in apparent clinical improvements over a 2 year follow-up .

Table 1. Clinical parameters of rheumatoid arthritis patients.

Parameter Follow-up time (months)
 0 (n=42)  3 (n=42)  6 (n=42)  12 (n=42)  18 (n=32)  24 (n=22)
 COE (mm/h)  38.41±2.20  31.12±1.94**  22.81±1.26**  21.75±1.60**  20.19±1.74**  21.14±2.12**
 Hb (g/L)  107.80±1.45  113.70±1.25**  120.81±1.01**  125.20±0.98**  126.42±1.17**  126.46±1.88**
 DAS 28  5.92±0.13  4.93±0.16**  3.34±0.18**  2.99±0.17**  2.96±0.21**  3.12±0.27**

In conclusion. rheumatoid arthritis patients with early and advanced stages of the disease can obtain significant clinical benefits due to the application of autologous T cell vaccination.